This is a StreetInsider.com Premium Only Page

Curis (CRIS) – Company Press Releases

Apr 5, 2024 07:30 AM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 4, 2024 07:30 AM Curis to Present at Upcoming Healthcare Conferences in April

Feb 8, 2024 08:00 AM Curis Provides Fourth Quarter 2023 Business Update

Feb 1, 2024 08:00 AM Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

Jan 5, 2024 08:00 AM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 12, 2023 08:00 AM Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Dec 11, 2023 08:00 AM Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Dec 6, 2023 08:00 AM Curis Announces Three Presentations at ASH

Dec 5, 2023 08:00 AM Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Nov 2, 2023 08:00 AM Curis Provides Third Quarter 2023 Business Update

Oct 26, 2023 08:30 AM Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

Oct 6, 2023 08:56 AM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sep 12, 2023 08:00 AM Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Sep 6, 2023 08:13 AM Curis to Present at Upcoming Healthcare Conferences in September

Aug 3, 2023 04:01 PM Curis Provides Second Quarter 2023 Business Update

Jul 27, 2023 06:25 PM Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

Jul 6, 2023 08:01 AM FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

Jul 6, 2023 08:00 AM Curis Announces $15.1 Million Registered Direct Offering

May 5, 2023 07:30 AM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 4, 2023 04:01 PM Curis Provides First Quarter 2023 Business Update

Apr 27, 2023 04:01 PM Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023

Apr 5, 2023 08:13 PM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 3, 2023 08:00 AM Curis to Present at Upcoming Healthcare Conferences in April

Mar 13, 2023 08:00 AM Curis Provides Fourth Quarter 2022 Business Update

Mar 8, 2023 07:09 PM Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

Mar 2, 2023 04:01 PM Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023

Dec 12, 2022 10:00 AM Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Dec 5, 2022 11:08 PM Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

Nov 9, 2022 04:01 PM Curis Provides Third Quarter 2022 Business Update

Nov 7, 2022 04:01 PM Curis Announces Three Presentations at SITC 2022

Nov 2, 2022 04:00 PM Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022

Oct 7, 2022 04:01 PM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Oct 3, 2022 04:01 PM Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

Sep 19, 2022 09:16 PM Curis Announces Date for the 2nd Annual VISTA Symposium

Sep 7, 2022 08:00 AM Curis to Present at Upcoming Healthcare Conferences in September

Aug 30, 2022 08:00 AM FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study

Aug 18, 2022 08:00 AM FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

Aug 4, 2022 04:01 PM Curis Reports Second Quarter 2022 Financial Results and Business Update

Jul 29, 2022 04:00 PM Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 28, 2022 04:00 PM Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

Jul 7, 2022 04:01 PM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 10, 2022 07:00 AM Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress

Jun 4, 2022 09:00 AM Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Jun 2, 2022 08:00 AM Curis to Present at 2022 Jefferies Global Healthcare Conference

May 12, 2022 10:26 AM Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

May 5, 2022 04:01 PM Curis Reports First Quarter 2022 Financial Results and Business Update

Apr 28, 2022 04:00 PM Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022

Apr 11, 2022 08:00 AM Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)

Apr 7, 2022 04:01 PM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 5, 2022 08:00 AM Curis to Present at 21st Annual Needham Virtual Healthcare Conference